Table 3. Stratified analyses between rs1799750 polymorphisms and the risk of RCT.

Variable	rs1799750 (case/control)			1G/2G vs. 1G/1G	2G/2G vs. 1G/1G	2G/2G vs. 1G/1G +CT	2G/2G +1G/2G vs. 1G/1G
	1G/1G	1G/2G	2G/2G
Sex
Male	17/22	43/34	21/13	1.64 (0.75–3.56); 0.214	2.09 (0.82–5.34); 0.123	1.51 (0.69–3.30); 0.303	1.76 (0.84–3.68); 0.132
Female	20/28	31/39	17/12	1.11 (0.53–2.34); 0.778	1.98 (0.78–5.06); 0.151	1.86 (0.82–4.24); 0.140	1.32 (0.66–2.64); 0.437
Smoking
Yes	17/21	36/18	17/8	2.47 (1.05–5.80); 0.038	2.63 (0.91–7.55); 0.073	1.56 (0.61–3.99); 0.350	2.52 (1.14–5.57); 0.023
No	20/29	38/55	21/17	1.00 (0.50–2.03); 0.996	1.79 (0.76–4.22); 0.182	1.79 (0.87–3.68); 0.114	1.19 (0.61–2.31); 0.612
Alcohol
Yes	20/22	43/26	20/5	1.82 (0.84–3.96); 0.131	4.40 (1.39–13.92); 0.012	3.05 (1.07–8.70); 0.037	2.24 (1.06–4.70); 0.034
No	17/28	31/47	18/20	1.09 (0.51–2.31); 0.830	1.48 (0.62–3.56); 0.379	1.41 (0.68–2.93); 0.362	1.21 (0.59–2.44); 0.606
Age (years)
<60	31/31	52/49	27/16	1.06 (0.56–2.00); 0.854	1.69 (0.76–3.73); 0.196	1.63 (0.82–3.24); 0.168	1.22 (0.67–2.21); 0.521
≥60	6/19	22/24	11/9	2.90 (0.98–8.59); 0.054	3.87 (1.09–13.81); 0.037	1.88 (0.69–5.11); 0.218	3.17 (1.12–8.93); 0.029
Hypertension
Yes	9/13	27/22	7/5	1.77 (0.64–4.92); 0.271	2.02 (0.49–8.43); 0.334	1.36 (0.40–4.70); 0.626	1.82 (0.68–4.89); 0.236
No	28/37	47/51	31/20	1.22 (0.65–2.29); 0.541	2.05 (0.97–4.32); 0.060	1.82 (0.96–3.45); 0.067	1.45 (0.81–2.61); 0.213
Diabetes
Yes	10/6	23/16	6/1	0.86 (0.26-2.85); 0.809	3.60 (0.35-37.60); 0.285	4.00 (0.45-35.54); 0.214	1.02 (0.32-3.32); 0.969
No	27/44	51/57	32/24	1.46 (0.79-2.68); 0.226	2.17 (1.06-4.44); 0.031	1.73 (0.94-3.17); 0.077	1.67 (0.95-2.95); 0.077
Thyroid disease
Yes	1/2	6/9	4/1	1.33 (0.10-18.19); 0.829	8.00 (0.31-206.36); 0.210	6.29 (0.58-68.42); 0.131	2.00 (0.16-25.75); 0.595
No	35/48	68/64	34/24	1.42 (0.82–2.46); 0.215	1.89 (0.96–3.72); 0.066	1.53 (0.85–2.74); 0.158	1.55 (0.92–2.59); 0.099

Bold values are statistically significant (P<0.05).